Oct 21, 2026
OpenAI describes thousands of GPT-Rosalind agents analyzing existing mouse-brain CRISPR data in 32 minutes, combining cellular responses and scientific literature into a reasoning atlas.
Distributed analysis surfaces hypotheses for follow-up experiments, including a possible cholesterol-transport link to neurodegeneration. These are research leads, not confirmed treatments. The accompanying agent software is released under MIT; that does not make GPT-Rosalind weights open.